Law heavyweight Greenberg Traurig is acting as counsel for ONO Pharmaceutical in its acquisition of Deciphera, a US cancer drugmaker, for a deal amounting to $2.4 billion. Details of the transaction reveal that ONO will purchase all outstanding shares of Deciphera for $25.60 per share in cash. Law.com reports that Deciphera, which was founded in 2003, places its emphasis on the development of cancer drugs.
Representing Deciphera’s interests in the transaction is Goodwin Procter, another prominent player in the legal field. Despite the intricate details of the agreement remaining undisclosed thanks to a paywall, the significance of this deal in the pharmaceutical industry is clear. As law firms continue to facilitate these major transactions, they affirm the vital role legal experts play in the global economy and the pharmaceutical industry.